Grant: Discovery Grants Program - Individual
Université de Montréal
$165,000.00
New methods for the stereoselective sythesis of organic compounds
FY 2006-07
Summary
Our research program aims at developing new and efficient methods for the selective synthesis of compounds containing mostly carbon, hydrogen, oxygen and nitrogen (regio-, chemo-, enantio- and diasteroselective). The basic theme is to come up with efficient synthetic methods that will allow the preparation of only one of the two possible enantiomer of a chiral molecule. The majority of bioactive and naturally occuring organic compounds are chiral, and, therefore, two similar structures that are non superimposable mirror image of one another exist. These are the most challenging compounds to selectively synthesize due to the inherent similarity between various chemical structures. We are interested in the development of new chiral reagents and, ultimately, of chiral catalysts to efficiently synthesize them. This area is extremely important since chiral, non-racemic compounds are essential components in pharmaceuticals, agrochemical, biochemicals and in material sciences. For a practical example, some new and very important drugs such as those used in the HIV combination therapy (AZT, 3TC, Indinavir) are highly complex molecules. The perspective of generating new methods to facilitate access to complex enantiopure products is an extremely important goal, and this proposal will directly address this issue. More specifically, we will concentrate our efforts on the development of new catalysts for cyclopropane formation as well as for other pharmaceutically important pharmacophores. The new methods will also be highlighted in natural product synthesis. Given the high concentration of phamaceutical companies and internationally renowned research centers in the Greater Montreal area, this program will naturally strengthen and complement existing R&D programs, thus ensure Canada's leadership in the field of medicinal chemistry and pharmacology. As well, in addition to creating a critical mass of highly qualified scientists, the potential application of discoveries that will emerge from the program will open the door to innovation that will help Canada's pharmaceutical companies hone their competitive edge in the global economy.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
156359-2006
Name nom
Charette, André
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2006
Competition year année de concours
2006
Award amount
165000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
5
Application title
New methods for the stereoselective sythesis of organic compounds
Keyword
NA
Application summary
Our research program aims at developing new and efficient methods for the selective synthesis of compounds containing mostly carbon, hydrogen, oxygen and nitrogen (regio-, chemo-, enantio- and diasteroselective). The basic theme is to come up with efficient synthetic methods that will allow the preparation of only one of the two possible enantiomer of a chiral molecule. The majority of bioactive and naturally occuring organic compounds are chiral, and, therefore, two similar structures that are non superimposable mirror image of one another exist. These are the most challenging compounds to selectively synthesize due to the inherent similarity between various chemical structures. We are interested in the development of new chiral reagents and, ultimately, of chiral catalysts to efficiently synthesize them. This area is extremely important since chiral, non-racemic compounds are essential components in pharmaceuticals, agrochemical, biochemicals and in material sciences. For a practical example, some new and very important drugs such as those used in the HIV combination therapy (AZT, 3TC, Indinavir) are highly complex molecules. The perspective of generating new methods to facilitate access to complex enantiopure products is an extremely important goal, and this proposal will directly address this issue. More specifically, we will concentrate our efforts on the development of new catalysts for cyclopropane formation as well as for other pharmaceutically important pharmacophores. The new methods will also be highlighted in natural product synthesis. Given the high concentration of phamaceutical companies and internationally renowned research centers in the Greater Montreal area, this program will naturally strengthen and complement existing R&D programs, thus ensure Canada's leadership in the field of medicinal chemistry and pharmacology. As well, in addition to creating a critical mass of highly qualified scientists, the potential application of discoveries that will emerge from the program will open the door to innovation that will help Canada's pharmaceutical companies hone their competitive edge in the global economy.